2.Generation of Japanese Encephalitis Virus-like Particle Vaccine and Preliminary Evaluation of Its Protective Efficiency.
Yanfang ZHANG ; Ruikun DU ; Shaomei HUANG ; Tao ZHANG ; Jinliang LIU ; Bibo ZHU ; Hualin WANG ; Fei DENG ; Shengbo CAO
Chinese Journal of Virology 2016;32(2):150-155
The cDNA fragment of JEV prME gene was cloned into the baculovirus shuttle vector (bacmid) to construct a recombinant baculovirus vector, defined as AcBac-prME. Then the recombinant baculovirus Ac-prME was obtained by transfecting Sf9 cells with AcBac-prME. Western blot analysis and immunofluorescence results indicated that both prM and E proteins were efficiently expressed in Sf9 cells. Electron microscopy suggested that prME was assembled into JEV-VLPs. To further evaluate the potential of JEV-VLPs as vaccine, the mice were immunized with JEV-VLPs and then challenged with lethal JEV. The results of mice survival and pathological changes demonstrated that the JEV-VLPs performed complete protection against JEV-P3 strain and relieved pathological changes in the mice brain significant. This study suggest that JEV-VLPs would be a potential vaccine for Japanese encephalitis virus.
Animals
;
Antibodies, Viral
;
immunology
;
Encephalitis Virus, Japanese
;
genetics
;
immunology
;
Encephalitis, Japanese
;
immunology
;
prevention & control
;
virology
;
Humans
;
Japanese Encephalitis Vaccines
;
administration & dosage
;
genetics
;
immunology
;
Mice
;
Mice, Inbred BALB C
;
Sf9 Cells
;
Vaccination
;
Vaccines, Virus-Like Particle
;
administration & dosage
;
genetics
;
immunology
;
Viral Envelope Proteins
;
administration & dosage
;
genetics
;
immunology
3.Production and immunogenicity of chimeric virus-like particles containing the spike glycoprotein of infectious bronchitis virus.
Lishan LV ; Xiaoming LI ; Genmei LIU ; Ran LI ; Qiliang LIU ; Huifang SHEN ; Wei WANG ; Chunyi XUE ; Yongchang CAO
Journal of Veterinary Science 2014;15(2):209-216
Infectious bronchitis virus (IBV) poses a severe threat to the poultry industry and causes heavy economic losses worldwide. Vaccination is the most effective method of preventing infection and controlling the spread of IBV, but currently available inactivated and attenuated virus vaccines have some disadvantages. We developed a chimeric virus-like particle (VLP)-based candidate vaccine for IBV protection. The chimeric VLP was composed of matrix 1 protein from avian influenza H5N1 virus and a fusion protein neuraminidase (NA)/spike 1 (S1) that was generated by fusing IBV S1 protein to the cytoplasmic and transmembrane domains of NA protein of avian influenza H5N1 virus. The chimeric VLPs elicited significantly higher S1-specific antibody responses in intramuscularly immunized mice and chickens than inactivated IBV viruses. Furthermore, the chimeric VLPs induced significantly higher neutralization antibody levels than inactivated H120 virus in SPF chickens. Finally, the chimeric VLPs induced significantly higher IL-4 production in mice. These results demonstrate that chimeric VLPs have the potential for use in vaccines against IBV infection.
Animals
;
Antibodies, Viral/blood
;
*Chickens
;
Chimera/genetics/immunology
;
Coronavirus Infections/prevention & control/*veterinary/virology
;
Female
;
*Immunity, Innate
;
Infectious bronchitis virus/genetics/*immunology
;
Influenza A Virus, H5N1 Subtype/genetics/immunology
;
Injections, Intramuscular/veterinary
;
Mice
;
Mice, Inbred BALB C
;
Neuraminidase/genetics
;
Poultry Diseases/*prevention & control/virology
;
Recombinant Fusion Proteins/genetics/immunology
;
Spike Glycoprotein, Coronavirus/genetics/*immunology
;
Vaccines, Synthetic/administration & dosage/genetics/immunology
;
Vaccines, Virus-Like Particle/administration & dosage/genetics/*immunology
;
Viral Proteins/genetics